Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 05/31 05:57:01 pm
112.36 USD   -0.62%
05:37p JOHNSON & JOHNS : European Commission Approves TREVICTA® (paliperido..
05/30 JOHNSON & JOHNS : Canadian class-action launched over Johnson & John..
05/30 Samsung Bioepis receives final European approval for its Remicade..
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Recalls Nearly 54,000 Packages Of Imodium Antidiarrhea Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
05/17/2012 | 07:41pm CEST
   By Peter Loftus 

Johnson & Johnson (JNJ) has recalled nearly 54,000 packages of Imodium Multi-Symptom Relief antidiarrhea pills due to a potential packaging defect.

J&J's McNeil consumer-health division said Thursday an internal review revealed the potential for a limited number of blister-packaging units--which contain the pills--to have dents with a small pinhole or tear.

J&J said the voluntary recall was being conducted at the wholesale level only, and not from consumers or store shelves. J&J said there were no safety concerns or adverse events associated with the recall.

The company said consumers may continue to use the product if there is no hole or tear in the blister unit. An Imodium caplet taken from a damaged blister unit, however, may not provide the full benefit of the product as intended. J&J advised patients not to take the product if the blister unit is torn or open.

J&J said it has made improvements to the packaging line to try to prevent the issue from happening again.

J&J has manufactured more than 2.75 million packages of Imodium Multi-Symptom Relief Caplets over the past five months, and except for the one lot being recalled, the product remains on store shelves, said spokeswoman Barbara Montresor.

J&J's McNeil unit has issued a series of recalls for popular over-the-counter medicines like Tylenol over the past two and a half years for various quality lapses. The recalls have cost the company hundreds of millions of dollars in lost sales and costs to fix the manufacturing problems.

More information about the recall can be found at the Imodium product website: http://www.imodium.com/page.jhtml?id=imodium/include/news.inc.

J&J shares rose 0.2% to $63.81 in recent trading.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
React to this article
Latest news on JOHNSON & JOHNSON
05:37p JOHNSON & JOHNSON : European Commission Approves TREVICTA® (paliperidone palmita..
05/30 JOHNSON & JOHNSON : Canadian class-action launched over Johnson & Johnsons baby ..
05/30 Samsung Bioepis receives final European approval for its Remicade copy
05/29 JOHNSON & JOHNSON : Telling the stories of a son fallen in combat, and also vete..
05/27 JOHNSON & JOHNSON : SIMPONI® Receives CHMP Positive Opinion For Treatment Of Pol..
05/27 JOHNSON & JOHNSON : Remember these? Pinto, Tylenol and other infamous recalls
05/27 JOHNSON & JOHNSON : Canadian class action claims Johnson's baby powder failed to..
05/27 MYOB : Australia’s Best Employers Revealed
05/26 JOHNSON & JOHNSON : Pharma company developing cancer drug moving to Houston
05/25 JOHNSON & JOHNSON : to Participate in the Goldman Sachs 37th Annual Global Healt..
News chart
Full-screen chart
Income Statement Evolution
More Financials